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Objectives: To establish a consensus defined daily dose animal (DDDA) for each active substance (AS) and admin-
istration route for porcine veterinary antimicrobial products authorized in four European countries, thus allowing
cross-country quantification and comparison of antimicrobial usage data.
Methods: All veterinary antimicrobial products authorized for porcine use in Belgium, France, Germany and
Sweden were listed for each administration route. First, separate DDDAs for each product were defined based
on the recommended dosing for the main indication. Second, a consensus DDDA was established by taking
the mean of the DDDAs for each product within a certain category of AS plus administration route.
Results: One-hundred-and-fifty-nine, 240, 281 and 50 antimicrobial products were licensed in Belgium, France,
Germany and Sweden, respectively, in February 2013. Large variations were observed for dosage and treatment
duration recommendations between products and between countries for the same ASs. Only 6.8% of feed/water
and 29.4% of parenteral AS groups had the same recommended dosage in the four countries.
Conclusions: This study presents a consensus DDDA list for use in the quantification and comparison of antimicro-
bial consumption. Four major recommendations have been formulated: (i) urgent need for harmonization of
authorization and recommended summary of product characteristics (SPC) dosages; (ii) expand the developed
preliminary DDDA list to include all authorized veterinary medicinal products in all EU member states and for all
(food-producing) animal species; (iii) improved accessibility of country-specific SPC data would be preferable; and
(iv) statement of the ‘long-acting’ duration of a product in the SPC.
Keywords: antimicrobial usage quantification, cross-country comparison, defined course dose animal, defined daily dose animal,
porcine antimicrobial products
Introduction
Antimicrobial usage in food-producing animals is high on the
European scientific and political agendas.1 Of major concern is
the development and selection of antimicrobial resistance in bac-
teria, impeding the adequate treatment of bacterial infections in
animals and humans. A recent paper described a strong correlation
between the level of animal antimicrobial usage and the level of
resistance in commensal Escherichia coli at the national level.2 A
meta-analysis in human medicine has also described an associ-
ation between antibiotic consumption and the development of
antibiotic resistance.3 The WHO refers to antimicrobial resistance
as a global concern and emphasizes the importance of reliable
data collection and monitoring systems.4 When establishing
these monitoring systems, harmonization of both antimicrobial
consumption quantification and resistance determination is crucial
for enabling objective comparisons and risk assessments within
and between countries.
Gaining insight into the amount of antimicrobials used in live-
stock production requires an accepted method for objective com-
parison across animal species within and between countries in a
way that represents the antimicrobial resistance selection pres-
sure that is exerted in the best possible way. Given the huge differ-
ences in molecular weight among antimicrobial compounds, the
use of a weight parameter such as the milligram or kilogram is not
advisable. The European Surveillance of Veterinary Antimicrobial
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Consumption (ESVAC) consortium of the EMA has recently pro-
posed the use of the defined daily dose animal (DDDA) as a quan-
tification unit of antimicrobial consumption.5 This measure is
derived from the established method of the defined daily dose
(DDD)6 used in human medicine since 1991. In human medicine
the DDD is defined by the WHO as ‘the assumed average mainten-
ance dose per day for a drug used for its main indication in
adults’.6
In veterinary medicine, the ESVAC consortium has defined the
DDDA as ‘the assumed average maintenance dose per day per kg
body weight for the main indication in a specified species’.7 The
defined course dose animal (DCDA) is defined as ‘the assumed
average maintenance dose per day per kg body weight for the
main indication in a specified species (DDDA) multiplied by the
assumed duration of treatment’.7
In its 2012 reflection paper,5 ESVAC requests the development
of a standardized DDDA list among EU member states. To the
best of our knowledge this list has not been developed yet.
Quantification and cross-country analysis of antimicrobial usage
in pig production in several EU countries is one of the aims of
the MINAPIG consortium (www.minapig.eu). Assigning DDDAs
for antimicrobials used in pig production was therefore a neces-
sary first step. Use of the DCDA is another method for describing
antimicrobial usage, which incorporates treatment duration.
Establishment of the DCDA was therefore considered a useful add-
ition to the established DDDA. ESVAC also mentions the use of the
DCDA in its reflection paper.5
The aim of this article is to describe the procedures used to
assign standardized DDDAs for four EU countries and to highlight
the differences found within and between countries in dosage
recommendations for the same active compounds and adminis-
tration route combinations. The consensus DDDA is not to be seen
as a gold standard or as a tool to assess prudent antimicrobial
usage, but rather as a reference point for quantification of anti-
microbial usage in a standardized manner across different
countries.
Materials and methods
Data collection
Antimicrobial products authorized for use in pig production in February
2013 were listed for Belgium, Germany, France and Sweden. These data
were obtained from the national regulatory institutions involved in the
authorization and registration of veterinary medicinal products. In
Belgium this is Het Belgische Centrum voor Farmacotherapeutische
Informatie (BCFI vet),8 for France it is the Index des Médicaments
vétérinaires autorisés en France (IRCP)9 and for Sweden it is either
Fakta för förskrivare (FASS)10 or Läkemedelsverket.11 For Germany
the university service Veterinärmedizinischer Informationsdienst für
Arzneimittelanwendung, Toxikologie und Arzneimittelrecht (Vetidata)12
was used. For each authorized product, detailed information on the active
substances (ASs) in the product, the concentration, the administration
route, long-acting (LA) activity (i.e. the duration of activity of an AS after
administration of a dose) and whether the AS is categorized as critically
important by the WHO13 or World Organisation for Animal Health (OIE)14
were recorded. A total of six administration routes were differentiated:
feed/water, oral non-feed/water (i.e. drench, tablet), parenteral, topical,
topical eye ointment and intrauterine.
In this paper antimicrobials are defined as products with an antimicro-
bial mechanism of action falling within WHO ATCvet first level codes15 QD,
QG, QJ and QS.10 Zinc oxide was considered separately, since this is con-
sidered to be an alternative to antimicrobials in pig production in some EU
countries. During the data collection zinc oxide was only authorized in
Sweden. In Germany zinc oxide was only available in combination with
colistin and in Belgium zinc oxide was only allowed as a single in-feed addi-
tive from September 2013 onwards.
Method of DDDA determination for individual products
A DDDA was assigned for each individual antimicrobial product authorized,
based on the dosage for the main indication provided in the country-
specific summary of product characteristics (SPC). In guidelines, prudent
antimicrobial use is described as using the products in accordance with
the SPC.16 – 18 The recommended dosage is therefore the dosage recom-
mended by the licence holder and might not be the proposed dosage
based on the scientific literature. The DDDA was listed in mg/kg body
weight (mg/kg) and per day. Doses of products with an AS expressed in
IU in their SPC were recalculated to mg/kg using the conversion rates pub-
lished in the second ESVAC report.19
When a clear main indication was stated in the SPC, this dosage was
used to assign the product DDDA. The specified main indications used are
listed in Table 1. In a few cases the main indication in the SPC varied
between countries. In these cases the main indication was agreed upon
by consensus, mainly after consulting pharmaceutical laboratories.
When a dosage range was given in the SPC, the mean of the minimal
and maximal dosages was selected. If no indication was listed and a
range was provided, the mean value was also used.
If the SPC stated a double or even triple daily treatment with the same
dosage in severe cases, it was, by consensus, agreed upon that the DDDA
would consist of the mean of the normal daily dose and the double dose.
Treatment duration was also listed for each product. By the same pro-
cedure as for the DDDA assignment, the main indication was used to set
the treatment duration. If the SPC provided a range or there was a discrep-
ancy in main indication, the mean of the minimal and maximal recom-
mended treatment durations was taken.
DDDAs for combination products were determined as the sum of the
DDDAs for the separate ASs. Zinc oxide was also included if it was com-
bined with an antimicrobial AS. Using the same procedure as that used
for products with a single AS, the mean was calculated if there was a
range, and when a clear main indication was stated this value was used.
LA products received an LA factor (i.e. value that represents the dur-
ation of activity of an LA product) depending on the estimated duration
of antimicrobial activity to determine the number of DDDAs resulting
from one treatment. These LA factors were assigned based on available
research information in the European Public Assessment Reports (EPAR)
Table 1. Main indications from SPCs for ASs with several dosage
recommendations for different indications; the recommended dosage for
the main indication was chosen for further analysis
AS
Administration
route Main indication
Lincomycin feed/water enzootic pneumonia
Lincomycin+
spectinomycin
feed/water dysentery
Tiamulin feed/water dysentery
Tiamulin parenteral dysentery
Tylosin feed/water porcine proliferative enteropathy
Tylvalosin feed/water dysentery
Valnemulin feed/water dysentery
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of the EMA or the treatment interval described in the SPC. When a clear,
single duration of action for an LA product was not provided from this
information, but an indication of the duration range was provided, the
authors assigned the LA factor in consensus based on scientific literature
data.
For topical spray or eye products it was assumed that 3 mL of product
would be used per treatment. This was based on the assumption that
1 mL will be sprayed per second and the fact that 3 s of spraying is the
average duration mentioned in the SPCs for topical spray products.20 – 31
For two out of three intrauterine products no information on the weight
of a tablet could be traced. Therefore, these DDDAs were assigned assum-
ing administration of one tablet as treatment for an average sow of 220 kg
body weight, similar to the weights advised by ESVAC.5
The critical importance of a product was also listed, following the
guidelines of the WHO13 and OIE14 for human and veterinary usage,
respectively.
Assigning DDDAs across countries
The chapter ‘Assignment of DDDAs and DCDA values’ of the ESVAC reflec-
tion paper on collecting data on consumption of antimicrobial agents for
each animal species5 was used as a guideline to assign DDDAs over the
four countries.
An individual product was first categorized based on its AS(s) and sub-
sequently on its administration route. Products were also categorized
based on whether or not they were LA products. No differentiation in
DDDA was made for different age categories. Recommended dosages
are normally not differentiated for different age categories. In the rare
cases in which the SPC mentioned different dosages for piglets and
adult animals we chose to use the recommended dosage for adult ani-
mals. This is in accordance with the procedure used in human medicine,
where the DDD is assigned based on use of a medicinal product by an aver-
age adult person.6
The mean, median and mode were calculated for all products within
each AS plus administration route category. The mean was considered
to be the consensus DDDA. The same procedure was used to establish
the LA factors and treatment duration. Important differences in recom-
mended dosage and treatment duration for the individual products com-
pared with the consensus DDDAs and DCDAs were identified.
Data analysis
Data were managed using Microsoft Excel 2010 and further analysed
using IBM SPSS Statistics version 22. For each product, the difference
between its DDDA and the assigned mean consensus DDDA was calcu-
lated. Differences of .10% from the consensus DDDA in AS plus adminis-
tration route categories with at least two products in two different
countries were analysed with a univariate general linear model to check
for the effects of number of years since first authorization and country.
Comparison between countries regarding the deviation from the consen-
sus DDDA and treatment duration for each administration route was done
by using a non-parametric independent samples Kruskal–Wallis test with
pairwise comparison.
Results
DDDAs
There were 159, 240, 281 and 50 antimicrobial products licensed
in Belgium, France, Germany and Sweden, respectively, adding up
to a total of 730 products (Table 2). The oldest product was first
authorized in 1955, the newest in 2013. A total of 116 unique cat-
egories based on AS, administration route and LA factor were
identified, for which a DDDA and DCDA were assigned. There
were 82 groups of different antimicrobial ASs or combinations of
ASs combined with a similar administration route. Of these 82 AS
plus administration route categories, 44 (360 products) were
authorized for use in feed or water, 51 for parenteral administra-
tion (326 products), 3 (7 products) for intrauterine use, 11 (21 pro-
ducts) for oral non-feed/water use, 6 (15 products) for topical use
and 1 (1 product) for use as eye ointment. Fifty-seven of the ASs
were authorized for one administration route, 18 for two, 5 for
three and 2 for four administration routes.
The ASs with the most authorized products were colistin
(n¼53 products), amoxicillin (n¼49) and enrofloxacin (n¼44).
The number of authorized products does not necessarily equal
the usage of these products.
The list of consensus DDDAs and consensus DCDAs is provided
in Table S1 (available as Supplementary data at JAC Online).
For 11 of the 17 ASs with authorization for parenteral adminis-
tration as well as feed/water administration, the mean dosages
for parentally administered products were lower in comparison
with products administered by feed or water having the same
AS (Table 3).
Table 2 shows that 597 of 730 products (81.8%) are refereed by
the OIE as critically important for veterinary usage, and 442 pro-
ducts (60.5%) by the WHO as critically important for human usage.
Deviation from consensus DDDA
The percentage of products deviating .10% from the mean
consensus DDDA are listed per category based on AS and
Table 2. Number of antimicrobial products licensed for pigs for each country and administration route, including the number of products listed as
critically important by WHO13 or OIE14 for human or veterinary medicine, respectively
Administration route Belgium France Germany Sweden Total
Critically important
veterinary14
Critically important
human13
Feed/water 72 138 133 17 360 272 189
Parenteral 81 93 129 23 326 287 223
Oral non-feed/water 3 3 9 6 21 15 8
Topical 3 6 4 2 16 16 15
Intrauterine 0 0 6 1 7 7 7
Eye ointment 0 0 0 1 1 0 0
Total 159 240 281 50 730 597 442
Postma et al.
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administration route in Table S1. The number of products within a
category showing deviation varied from only one (4.9%) to all of the
products (100%). Thirty-one out of 82 unique combinations
showed deviations .10% from the consensus DDDA. The top 20
deviating products are listed in Table 4. This list includes mainly pro-
ducts containing tylosin, amoxicillin and doxycycline. Fifteen of
these top 20 deviating products were authorized in Germany.
Feed/water
Of the 44 AS categories authorized for feed/water administration,
3 (6.8%) did not deviate from the mean consensus DDDA because
they had the same SPC dosage recommendation in the countries.
These three harmonized feed/water categories were florfenicol
(Belgium, France, Germany), trimethoprim/sulfamethoxazole
(Belgium, Germany) and valnemulin (Belgium, Germany, Sweden).
For florfenicol there were two authorized commercial products
marketed by two different pharmaceutical companies. For
trimethoprim/sulfamethoxazole there was one product author-
ized in two countries, first authorized in 2012. Valnemulin was
represented by one product in three countries and was first
authorized in 1999.
One of the feed/water AS categories with large variations
between products in recommended dosage was tylosin, with a
10-fold difference between the minimum and maximum recom-
mended dosage. The product with the minimum dosage and the
product with the maximum dosage were both authorized in
Belgium. Tylosin feed/water products were authorized between
1975 and 2012. The authorization date did not explain the devi-
ation from the consensus DDDA (n¼33, P¼0.32), and neither did
country (P¼0.36). One Belgian tylosin product has a main indica-
tion of dysentery and a recommended dose of 45 mg/kg, while
the SPC of the other Belgian product mentions dysentery and por-
cine proliferative enteropathy (PHE), with the same recommended
dose of 4.5 mg/kg for both indications. This shows that for the
same indication (here dysentery) the recommended dose varies
between 4.5 and 45 mg/kg.
The combination of lincomycin with spectinomycin was also well
represented and was a clear example of large variation in DDDA
(minimum dosage 3.3 mg/kg, maximum dosage 10.0 mg/kg). The
authorization dates varied between 1975 and 1998 and could not
explain the deviation (n¼13, P¼0.81), and the country was not
decisive either (P¼0.33).
For some of the other feed/water products with a deviation of
.10% from the consensus DDDA, country explained the differ-
ence: amoxicillin (P¼0.02, Germany . France), chlortetracycline
(P,0.01, Germany . Belgium and Sweden), colistin (P,0.01,
Sweden . Belgium, Germany and France), neomycin (P,0.01,
France . Germany), sulfadimidine (P¼0.02, Germany . France),
tiamulin (P,0.01, Germany . Belgium, Sweden and France) and
trimethoprim/sulfadimethoxine (P,0.01, France . Germany).
The year of first authorization was only statistically explanatory
for feed/water sulfadimidine (P¼0.04).
Table S1 shows the complete list of AS plus administration route
categories including differences .10% from the consensus DDDA.
Parenteral
Of the 51 licensed AS plus administration route categories for par-
enteral administration, 29 did not deviate from the mean consen-
sus DDDA. For 14, this was because there was only one product
registered for this specific category whereas 15 categories con-
tained several products authorized in one or more countries.
Looking only at those categories containing multiple products,
we found 29.4% of parenteral products that had harmonized
registration over Belgium, France, Germany and Sweden.
Parenteral AS plus administration route categories with large
recommended dosage variations, such as amoxicillin (n¼13,
Table 3. Differences in feed/water dosage prescription compared with parenteral dosage prescription
AS Mean DDDA feed/water (n) Mean DDDA parenteral Difference Percentage differencea
Amoxicillin 20.4 (34) 11.7 (13) 8.7 +42.7
Ampicillin 32.0 (7) 17.0 (3) 15.0 +46.9
Colistin 5.0 (41) 2.6 (8) 2.4 +47.7
Enrofloxacin 1.7 (1) 2.8 (38) 21.1 262.5
Lincomycin 6.7 (7) 10.5 (11) 23.7 255.1
Lincomycin+spectinomycin 6.2 (13) 15.0 (6) 28.8 2140.7
Oxytetracycline 35.7 (19) 8.4 (8) 27.2 +76.3
Paromomycin 32.5 (1) 19.3 (1) 13.3 +40.8
Spiramycin 21.9 (2) 20.5 (3) 1.4 +6.3
Sulfadimethoxine 48.4 (2) 30.0 (1) 18.4 +38.0
Sulfadimidine 77.1 (12) 86.3 (3) 29.2 211.9
Tiamulin 7.8 (29) 9.3 (7) 21.5 218.7
Trimethoprim+sulfadiazine 29.8 (22) 18.1 (4) 11.7 +39.4
Trimethoprim+sulfadimethoxine 26.1 (7) 22.6 (1) 3.5 +13.5
Trimethoprim+sulfamethoxazole 25.0 (2) 30.0 (2) 25.0 220.0
Trimethoprim+sulfamethoxypyridazine 28.2 (1) 16.0 (1) 12.2 +43.3
Tylosin 14.9 (33) 10.4 (9) 4.5 +30.2
aA positive percentage difference means that the feed/water administration category of this AS had a higher mean recommended dosage; a negative
difference means that the parenteral recommended dosage was higher.
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minimum 7 mg/kg, maximum 20 mg/kg) and ampicillin (n¼3,
minimum 10 mg/kg, maximum 21 mg/kg), were authorized
between 1981 and 2005 and between 1983 and 1993, respect-
ively. For amoxicillin neither the number of years since first author-
ization (P¼0.29) nor country (P¼0.75) explained the deviation
from the consensus DDDA. On the other hand, the LA products
of amoxicillin also had a long authorization period and no devi-
ation occurred. Also for ampicillin, neither the first year of author-
ization (P¼0.39) nor the country (P¼0.61) was able to explain the
deviation.
For parenteral sulfadimidine, country significantly influenced
dosage (P¼0.03, France . Germany).
Year of first authorization (P¼0.04) as well as the country
(P¼0.01) were explanatory for differences in colistin (P¼0.04).
Parenteral colistin products were authorized in Belgium from
1978, while the first year of authorization for the French products
ranged from 1987 to 1998 and for Germany from 2001 onwards.
The mean recommended dosage was higher in Germany com-
pared with Belgium and France.
LA ceftiofur is an AS that was first authorized in 2005 and has
been granted a central marketing authorization by the European
Commission,32 and thus there was no variation between coun-
tries. The other products with central marketing authorization
were of the ASs tylvalosin, tulathromycin, valnemulin and tildipir-
osin. In the four countries the same product was authorized for
these specific ASs.
A general trend for the deviation from the consensus DDDA of
feed/water (P¼0.55) or parenteral (P¼0.78) products versus their
first year of authorization could not be found.
Intrauterine, oral non-feed/water, topical
For the 22 AS plus administration route categories authorized for
intrauterine, oral non-feed/water or topical administration or as
eye ointment there was no harmonization of the products.
Country or year of first authorization did not explain the .10%
deviation present.
Influence of countries on difference in dosage
There were marked differences between countries regarding
recommended dosages [e.g. spectinomycin, oral non-feed/water,
recommended dose 40 mg/kg in Belgium (n¼1) and 150 mg/kg
in Germany (n¼1)]. Even within the same country, the differences
for some ASs were huge (e.g. sulfaguanidine/sulfadimidine in
France, n¼2, minimum 38.4 mg/kg, maximum 160 mg/kg; tylo-
sin in Belgium, n¼7, minimum 4.5 mg/kg, maximum 45 mg/kg).
Some of these AS plus administration route categories were
unique to some countries (e.g. sulfaguanidine/sulfadimidine for
France).
Comparison between countries showed that the mean recom-
mended dose for feed/water administration compared with the
consensus DDDA was significantly lower in Germany than in
France (P¼0.03). For topical products, Sweden had high recom-
mended doses (mean deviation +36%) compared with the rela-
tively low recommended doses for Germany (mean deviation
219%), although the difference was not significant. The same
applied, to a lesser extent, to parenterally administered products
(mean deviation: Germany 23%, Sweden +12%, difference not
Table 4. Top 20 products deviating from the consensus DDDA
No. AS Administration route Country Product name
Deviation from
consensus DDDA (%)a
1 tylosin feed/water Belgium Tylosine 75% Kela +202.4
2 oxytetracycline feed/water Germany Ursocyclin-Pulver 20% +180.4
3 lincomycin feed/water Germany Lincomycinhydrochlorid Pulver 50% +122.6
4 tylosin feed/water Germany Klato lan, 1000 mg/g +101.6
5 tylosin feed/water Germany Tylogran WSP 1000 mg/g +101.6
6 tylosin feed/water Germany Tylosintartrat 100% +101.6
7 tylosin feed/water Germany Tylo-Suscit 100% Kompaktat +101.6
8 tylosin feed/water Germany Tylo-Suscit 25 +101.6
9 amoxicillin feed/water Germany Aciphen Kompaktat 1000 mg/g +96.0
10 amoxicillin feed/water Germany Amoxicillin-Trihydrat 100, 100% +96.0
11 amoxicillin feed/water Germany Amoxin 100 mg/g +96.0
12 amoxicillin feed/water Belgium Moxapulvis 50% +96.0
13 amoxicillin feed/water Germany Triamox 100 W 114,8 mg/g +96.0
14 tylosin parenteral Sweden Tylan vet. +92.5
15 tiamulin feed/water France Tiamuval Tiamuline 6,5 Entérite Porc 279.5
16 doxycycline feed/water Germany Doxy 50% (500 mg/g) +73.3
17 doxycycline feed/water Germany Pulmodox 500 mg/g +73.3
18 doxycycline feed/water France Pulmodox 500 mg/g +73.3
19 amoxicillin parenteral Germany Amoxicillin 15% WDT, 150 mg/mL +71.1
20 amoxicillin parenteral Germany Belamox 200 mg/mL +71.1
aA plus sign before the percentage deviation from the consensus DDDA means that this product had a higher recommended dosage compared with the
mean consensus DDDA; a minus sign means that the recommended dosage was lower.
Postma et al.
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significant). For feed/water products a non-significant mean devi-
ation of +9% for Germany and 210% for Sweden was seen. A sig-
nificantly higher recommended dose was observed for parentally
administered products in Sweden compared with France (P¼0.02)
and Germany (P¼0.03). Table 5 shows the deviations from the
consensus DDDA and the recommended mean duration over
countries.
Duration of treatment
Analysing deviations from the mean for treatment durations
showed the largest variation for feed/water-administered pro-
ducts (mean 7.5 days, minimum 3 days, maximum 42 days).
Products in the oral non-feed/water administration category in
Germany had a significantly longer treatment duration than in
Belgium (P,0.01). For parenteral products, the variation in treat-
ment duration (from 1 to 7 days) was not significantly different
between countries.
Discussion
Data collection, establishment of DDDAs
Although highly recommended and requested by ESVAC in their
latest reports, to date no other attempt has been described to
establish DDDAs across countries, as far as the authors are
aware. Even in human medicine only limited publications are
available on discrepancies in the DDDs used in human medi-
cine.33,34 The current paper documents the results of the exercise
for four EU countries. It may serve as a starting point for an
EU-wide DDDA list. However, the authors would like to state
clearly that the provided list of DDDAs is based on generalizations
and simplifications and therefore does not necessarily reflect the
true use in a herd or a country but rather provides a tool to allow
comparison between herds or countries. As regards dosing, we
argue that it is difficult to discuss the concepts of under- and over-
dosing objectively given the observed huge variety in recom-
mended dosages. The DDDA was not specifically developed to
describe under- or overdosing in the different countries but rather
to quantify the amount of exposure of animals to antimicrobials.
Lists of antimicrobial products authorized within countries are
subject to regular changes as products are updated for their
recommended dosages, no longer marketed or new products
are authorized. Products authorized in February 2013 were
taken into account in this paper. Newer products or recent
changes might not be accounted for. However, since the number
of products was substantial in most AS categories, the mean con-
sensus DDDA is not expected to be much influenced by possible
recent changes.
The mean for all authorized products with the same AS and
administration route was considered to be the most transparent
method of establishing consensus DDDAs. No important difference
in the number of products deviating .10% from the median or
mode was seen compared with using the mean. Using the mean
implies that there is an impact of the number of products within an
AS category authorized per country. Countries with a large number
of authorized products have a higher impact on the consensus
DDDA. Mean, median and mode are listed in Table S1.
The main indications were selected based on available scien-
tific information in the EPAR reports of the EMA and SPC and
were set by consensus between the authors. However, for some
of the products authorized in France the chosen main indication
was not clearly stated in the SPC. This might partially explain
the larger deviation from the mean DDDA for French products.
No obvious explanation could be found for the fact that 75% of
the top 20 deviating products were authorized in Germany.
However, one reason might be that Germany has more authorized
products, providing more scope for larger deviations.
Table 5. Percentage of consensus DDDA or mean treatment duration by country
Comparison/administration route
Proportion of consensus
dosage/duration (%)a SD n
Significant
difference from P valueb
DDDA/feed or water
Belgium 95.4 37.7 72
France 95.2 32.0 138 Germany 0.04
Germany 108.7 41.3 133
Sweden 89.9 27.7 17
DDDA/parenteral
Belgium 100.4 13.4 81
France 97.0 8.7 93 Sweden ,0.01
Germany 99.5 17.1 129 Sweden 0.02
Sweden 111.9 23.5 23
Treatment duration/oral non-feed or -water
Belgium 77.8 4.8 3 Germany ,0.01
France 86.7 23.1 3
Germany 107.2 10.9 9
Sweden 95.8 6.5 6
aThe consensus DDDA and the mean treatment duration are set to 100%.
bKruskal–Wallis test with pairwise comparison.
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Unique combinations licensed for administration via water or
feed were analysed together, since there are many products
that have licenses for both administration routes or are adminis-
tered by both routes under field circumstances. However, there
are also products for which the dosage differences between the
feed and water SPCs are huge. Splitting feed and water adminis-
tration routes would have enabled a more specific analysis of the
recommended dosage and treatment duration.
LA factors were in some cases established by consensus, e.g.
for LA tulathromycin and ceftiofur. Because consensus was
reached using the scientific literature, this was considered the
most appropriate approach. However, the EPAR reports on which
the consensus was based might not provide the most accurate
information, since, e.g. duration of activity might differ among
individual animals, disease indications, pharmacodynamics or
environmental conditions, but this uncertainty could not be
taken into account. For LA products it would be advisable that
the SPCs provide more detailed information on the expected dur-
ation of effect after administration of a dose.
Assumptions and simplifications
It was agreed to establish the mean consensus DDDA based on
the recommended dosage for usage of the product in an adult
animal for the main indication. This is in concordance with the
definition of the DDD, used in human medicine.15 Since there
were products for which the recommended dosage differed
among several indications, the choice of using the main indication
could have influenced our results. However, for reasons of simpli-
fication and to avoid creation of an exhaustive list it was decided
to use the recommended dosage for an adult animal and not to
consider the other indications or the dosage recommendations
for young animals.
The extent to which authorized products are actually marketed
and used, and used in concordance with the recommendations of
the SPC, could not be checked in a scientific way and is highly influ-
enced by the individual therapy prescription provided by the vet-
erinarian. Callens et al.35 reported recently that correctness of
dosing for antimicrobial products based on the recommendations
of the SPC is being circumvented in Belgium. The only certainty is
the authorization license of the product. This was therefore the
basis of this research.
In this study the number of authorized products was much
higher in Germany compared with Sweden. A consequence of
using the methodology described here is that a country with a lar-
ger number of products will theoretically have a greater influence
on the mean consensus DDDA. This is inevitable in the method-
ology used here, by which we tried to find a consensus DDDA
that would fit best the available data.
Some of the necessary assumptions could have been circum-
vented if more detailed information on these matters had been
provided in the SPCs. For example, knowledge of the amount of
product that is applied by using a topical spray can for 1 s would
help in the estimation of the total amount of AS used per treat-
ment. It is recommended that this information is provided in
future registration dossiers.
Differences in molecular formulation between products might
have influenced variation in the recommended dosage in the SPC.
To avoid the creation of an almost infinite list with enormous com-
plexity it was decided to compromise on this matter by presuming
the recommended dosage at AS level was the best feasible
information.
Number of products and variation
For some products, large deviations with respect to the mean
consensus DDDA were observed among ASs and administration
routes and between or within countries. This might influence
the outcomes of future antimicrobial usage calculations in
the individual countries compared with national data using
national DDDAs. However, using one harmonized DDDA list
is the only feasible way to make a correct cross-country
comparison.
That only 6.8% of feed/water and 29.4% of parenteral admin-
istration routes were harmonized between EU member states
indicates the urgent need for EU-wide harmonization. It also
strongly questions the concept of under- or overdosing for many
products since using a half dose (severe underdosing) of a specific
product from a specific company in one country may constitute
overdosing with the same active compound according to the
registration of another company. Comparison of antimicrobial
consumption data should be conducted transparently and
under the same restrictions in all countries. A uniform DDDA
could be one of the requirements for this. As long as the country-
specific DDDAs differ largely from the consensus DDDA, however,
we should take this into account in analysing comparisons of anti-
microbial usage data over countries.
The hypothesis was that country and number of years since
first authorization might influence a product’s recommended
dosage: country might have an effect due to differences in legis-
lation and testing requirements, and number of years since first
authorization date might have an effect due to new insights or
techniques.
The number of years since first authorization explains only
some of the variation in recommended dosages between groups
of ASs and administration routes. The country where the product
is authorized/marketed also explains some of the deviations
from the consensus DDDA. Yet most of the deviations of
.10% could not be explained by year of first authorization or
country. Differences in recommended dosage might be influ-
enced by differences in authorization procedures from year to
year and differences among countries or pharmaceutical com-
panies, although all have to comply with the rules set by the
EU commission, and hence the EMA.32 The authors could not
find a direct, plausible reason for the large differences in recom-
mended dosages for more recently authorized products.
Differences in bioavailability of the products might be among
the reasons for differences in the recommended doses.
However, in our attempt to develop a harmonized DDDA list
this is the type of complexity that could not be taken into
account to prevent the creation of an unworkably long list.
Country-specific authorization procedures and different solvents,
experimental circumstances or inoculation methods might
explain this variation; however, retrospective validation is not
possible.
The lack of distinction between feed- and water-administered
products might explain the differences in treatment duration
for these products as well as some of the deviation from the con-
sensus DDDA. In general, products administered through feed
have a longer recommended treatment duration compared with
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the same ASs administered via water. In future DDDA-establishing
exercises, consideration should be given to recording the feed
administration route separately from the water route.
Critically important ASs
It was noticed that the majority of products available in porcine
medicine are in the list of critically important antimicrobials
for either or both WHO and OIE. Their usage in veterinary
practice should be greatly reduced in the near future, according
to current discussions among risk managers and policy
makers.36
Application of the DDDA list
The DDDA list described in this article may serve as a starting point
for discussion about the establishment of DDDAs in EU countries.
The DDDAs can be used to make a comparable antimicrobial
usage calculation between countries. The description of the
approach and the path towards the establishment of the DDDA
list should help future researchers in their attempt to broaden
the list by adding more products from other EU countries or ani-
mal species.
Conclusions
Comparison of authorized antimicrobials for porcine veterinary
usage in four EU member states showed large variation in the
number and types of products as well as differences in recom-
mended dosages. Although the process was challenging, a
mean consensus DDDA was established for the first time for ASs
licensed in several EU countries. It enables future comparison of
antimicrobial usage data. Country and number of years since
first authorization are explanatory for only a small number of
ASs plus administration route categories that deviate largely
from the mean consensus DDDA or the recommended treatment
duration. Harmonization of authorization and SPC would strongly
improve the comparability of antimicrobial usage data within and
between countries.
We therefore make the following recommendations:
(i) Harmonization. The findings described in this paper could be
perceived as indicating a lack of knowledge on optimal treat-
ment dosage and duration. The porcine sector, as well as other
sectors, would benefit from increased European or even inter-
national harmonization for veterinary medicinal product
authorization, for both new and existing authorizations.
(ii) Involvement of all member states. Establishment of DDDAs
should be performed for all EU member states, based on
information from the national authorities.
(iii) Accessibility of data. Access (via the World Wide Web) to
country-specific databases of authorized products is limited
due to difficulties in traceability of data sources and language
barriers. An EU-wide centralized database would ease this
process.
(iv) LA factor. The duration of action of an LA product should be
established by the manufacturer of the product using a pro-
cedure similar to that used for the recommended dosage and
given in the SPC.
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